newsfilter
← Latest News
Earnings Call Transcripts·

Annual Meeting of Stockholders - PARK NATIONAL CORP

Ladies and gentlemen, will the meeting please come to order. I want to welcome all of you to the 2026 Annual Meeting of Shareholders of AngioDynamics, Inc. I'm Howard Donnelly, Chairman of the Board. This year we are again conducting our annual meeting virtually. Joining me virtually are Eric Honroth, President and Chief Executive Officer of the company and a member of our Board of Directors. Eileen Owen, a member or Board of Directors and the incoming Chair of the board. and Larry Weiss, our Chief Legal Officer and Corporate Secretary. Also joining us virtually are the following directors of the company, LaRanger Burgess, Wes Johnson, Karen LaCitra, Jan Reed, and Dr. Michael Tarnoff. Our Corporate Secretary will file the proof of notice of this meeting with the minutes. Larry has informed me that there is a quorum present. The list of shareholders of record at the close of business on Friday, September 18, 2026, The record date of the annual meeting, certified by CompuShare as transfer agent, is available for inspection by any stockholder who desires to do so. It will be filed with the records of the company. As you enter the virtual meeting room, you should see an agenda and rules that will govern the meeting. We ask that any stockholders who wish to address the meeting please focus their comments on the item of the agenda that is before us. When any stockholder desires to ask a question or speak to the meeting, please follow the instructions on the portal to submit your written questions. Stockholders who are voting by proxy need not cast ballots in the voting today unless they wish to change the vote on their proxies. Please follow the instruction on the web portal. The company has appointed an inspector to conduct the voting at this meeting. That inspector is our Chief Legal Officer, Larry Weiss, who is present and has taken the oath of office. Polls for each matter voted on at this meeting are now open, and will close following the vote on the last proposal presented to the meeting. Until the polls close, any stockholder may change his or her prior vote on any matter. However, upon closing of the polls, no ballots, proxies, or votes, nor any replication or changes will be accepted. The next item on the order of business is the election of two Class II directors. set forth in the proxy statement for our annual meeting, the Board of Directors, acting on the recommendation of the Board's Nominating, Compliance, and Corporate Governance Committee, has elected as two class directors, Eileen Owen and Jan Sternreid, to serve until 2029 annual meeting of shareholders and until the respective successor are duly elected and qualified. The nomination as set forth from the proxy state is now before the meeting. The company has an advance notice provision in its bylaws for stockholder nominations of directors at the annual meeting. As the company has not received any notices, the nomination for directors are now closed. The meeting will now vote on the election of two Class II directors. The inspector will tabulate the votes for the election of the directors and report on the vote later in the meeting. The meeting will now proceed to Proposal 2 concerning the ratification of the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the current fiscal year. The proposal is outlined in the proxy statement and is now before the meeting. Are there any comments on the proposal? If there is no further discussion, the meeting will now vote on the proposed proposal to ratify the appointment of Deloit & Touze LLP as the country's independent registered public account firm for the present fiscal year The inspector will tabulate the votes for the proposal and report on the vote later in the meeting. The meeting will now proceed to Proposal 3, concerning a say-on-pay advisory vote on the approval of the compensation of AndroDynamics' named executive offices. The proposal is outlined in the proxy statement and is now before the meeting, are there any comments on the proposal? If there's no further discussion, the meeting will hold the say-on-pay advisory vote on the approval of the compensation of Angiodynamics' named executive offices. The inspector will tabulate the vote's proposal and report on the vote later in the meeting. The meeting will now proceed to Proposal 4, concerning the approval of an amendment to Angiodynamic's Inc. 2020 Equity Incentive Plan. The proposal is outlined in the proxy statement and is now before the meeting, Are there any comments on the proposal? If there is no further discussion, the meeting will now vote on the amendment to the Angiodynamics Inc. 2020 Equity Incentive Plan. The inspector will tabulate the votes for the proposal and report on the vote later in the meeting. The polls are now closed for each proposal voted upon at this meeting. The next item of order of business is the report of the inspector. Any votes collected during this meeting that are not included in the report or the inspector will be included in this company's current report on form 8K to be filed within four business days of the annual meeting. I now call upon the inspector to give the preliminary report of the inspector Mr. Chairman, from the report of the Inspector of Election, it appears that each of Eileen Allen and Jan Sternreid has been elected as a class two director of the company. The appointment of Deloitte and Touche LLP as the company's independent registered public accounting firm for the current fiscal year has been ratified. The say-on-pay advisory vote of the approval of the compensation of Angio Dynamics named executive officers has been approved, and the amendment to the Angio Dynamics Inc. 2020 equity incentive plan has been improved. I'd like to turn the meeting back over to Howard Donnelly, Chairman of the Company's Board of Directors, and Eileen Allen, the incoming Chair of the company's Board of Director. I want to thank all of you for attending today's meeting and for the interest you have shown in the affairs of your company. If there is nothing further to come before the meeting, the business of this meeting is adjourned. Before we close the call, I'd like to say a few words as I complete my time with AngioDynamics. my time on the board, this company has evolved and transformed into what I believe is an incredible company. It has been my privilege to be part of that journey as a member of the board and as chairman. As I retire from my role on the board, I am confident as ever about the future of this company. I'd like to now turn things over to Eileen Owen, the next chair of our board. Thank you, Howard. On behalf of all of us on the board, I want to thank you for your service to the company and for your leadership. It's really my privilege to succeed you as chair. As a member of the board for the last 10 years, I'm very grateful for the leadership that, Howard, you have provided as chairman and Jim Clemmer has as CEO, really positioning AngioDynamics for continued success. With Eric joining as our new CEO, I have more optimism for the future of angiodynamics than ever, and I'm very excited to see what we can accomplish next. And with that, operator, you can conclude the call. This concludes today's meeting. You may now disconnect.

Company
PARK NATIONAL CORP
Keywords
PARK NATIONAL CORP